TSE:NVC - Neovasc Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started Previous CloseC$1.74Today's RangeC$1.76 - C$1.8252-Week RangeC$0.49 - C$1.82Volume46,869 shsAverage Volume111,876 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartEarningsHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Neovasc Inc. (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company's segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products. The Tiara is in preclinical/early clinical stage development to provide a minimally invasive transcatheter device for patients experiencing mitral regurgitation (MR) as a result of mitral heart valve disease. The Reducer is an hourglass-shaped, balloon-expandable, stainless steel, bare metal device, which is implanted in the coronary sinus, creating a restriction in venous outflow from the myocardium (the muscular layer of the heart wall). Neovasc produces Peripatch, a biological tissue product that is manufactured from pericardium. Receive NVC News and Ratings via Email Sign-up to receive the latest news and ratings for NVC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange TSE Industry N/A Sub-IndustryN/A SectorN/A Current SymbolTSE:NVC Previous Symbol CUSIPN/A CIKN/A Webhttp://www.neovasc.com/ Phone+1-604-2704344Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings Date8/14/2019 (Estimated) OptionableNot Optionable Neovasc (TSE:NVC) Frequently Asked Questions What is Neovasc's stock symbol? Neovasc trades on the Toronto Stock Exchange (TSX) under the ticker symbol "NVC." How were Neovasc's earnings last quarter? Neovasc Inc. (TSE:NVC) announced its quarterly earnings data on Thursday, May, 9th. The company reported ($0.27) EPS for the quarter. The firm earned $0.78 million during the quarter, compared to analysts' expectations of $0.53 million. View Neovasc's Earnings History. When is Neovasc's next earnings date? Neovasc is scheduled to release their next quarterly earnings announcement on Wednesday, August 14th 2019. View Earnings Estimates for Neovasc. What is the consensus analysts' recommendation for Neovasc? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neovasc in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neovasc. Has Neovasc been receiving favorable news coverage? Headlines about NVC stock have been trending somewhat negative on Thursday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Neovasc earned a news sentiment score of -1.7 on InfoTrie's scale. They also gave news stories about the company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the near future. What other stocks do shareholders of Neovasc own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neovasc investors own include Neovasc (NVCN), PPL (PPL), Celator Pharmaceuticals (CPXX), Sophiris Bio (SPHS), Fc Global Realty (FCRE), TOP SHIPS (TOPS), Dundee Precious Metals (DPM), Ebix (EBIX), Computer Programs & Systems (CPSI) and Cellectar Biosciences (CLRB). Who are Neovasc's key executives? Neovasc's management team includes the folowing people: Paul L. Geyer, Independent Chairman of the BoardFred Colen, President, Chief Executive OfficerChristopher Clark, Chief Financial Officer, Corporate SecretaryBrian McPherson, Chief Operating OfficerVicki Lee Bebeau, Vice President - Clinical AffairsRandy Lane, Vice President - Research & DevelopmentAlexei J. Marko, DirectorJane H. Hsiao Ph.D., Independent Director (Age 69)Douglas Glen Janzen, Independent DirectorWilliam O'Neill, Independent Director (Age 61) How do I buy shares of Neovasc? Shares of NVC and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab. What is Neovasc's official website? The official website for Neovasc is http://www.neovasc.com/. How can I contact Neovasc? Neovasc's mailing address is 13562 Maycrest Way Suite 5138, RICHMOND, BC V6V 2J7, Canada. The company can be reached via phone at +1-604-2704344. MarketBeat Community Rating for Neovasc (TSE NVC)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 79 (Vote Outperform)Underperform Votes: 52 (Vote Underperform)Total Votes: 131MarketBeat's community ratings are surveys of what our community members think about Neovasc and other stocks. Vote "Outperform" if you believe NVC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/23/2019 by MarketBeat.com StaffFeatured Article: Are sell-side analysts objective? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.